News Industry News Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C June 25, 2015
News Daily News En Análisis ACCOAST Identifica los Factores asociados a Más Riesgos Hemorrágicos en el Manejo de Cuadros de SCASEST Todd Neale June 22, 2015
News Daily News ACCOAST Analysis Identifies Factors Tied to Higher Bleeding Risks in NSTE-ACS Todd Neale June 22, 2015
News Industry News New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets June 19, 2015
News Industry News First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit June 09, 2015
Presentation CATCH-UP 2015 Preventing Heart Failure Readmissions in the Era of Health Care Reform Presenter: Susan Woodley April 24, 2015
Presentation Economic Analysis of Ticagrelor TherapyFrom a US Perspective Presenter: Patricia A. Cowper February 02, 2015
News Daily News Long-term Ticagrelor Therapy Cost-Effective in US Patients L.A. McKeown February 02, 2015
News Daily News La IC Empeora los Resultados Post-SCA No observándose Beneficio alguno con Apixaban Todd Neale January 28, 2015
News Daily News HF Worsens Outcomes Following ACS, With No Benefit From Apixaban Todd Neale January 28, 2015
News Daily News Low Trial Participation Rate of MI Patients Raises Questions of Applicability Todd Neale September 02, 2014
News Daily News El Bajo Índice de Participación del Ensayo de Pacientes IM Plantea Dudas de Aplicabilidad Todd Neale September 02, 2014
Presentation Clinical Trial Participation After MI in a National Cardiovascular Data Registry Presenter: Jacob A. Udell August 27, 2014
News Daily News No Survival Difference Between One-Time, Staged PCI for Patients Without STEMI March 09, 2013
News Conference News ACC 2012 Color Coding, Checklists Improve Use of Evidence-Based Strategies for ACS L.A. McKeown March 25, 2012